Akebia Therapeutics (AKBA) reported $236M in revenue for fiscal 2025, +47.5% year on year. That ranks #2604 by revenue among 2853 SEC filers and #271 in Healthcare. It posted a net loss of −$5.3M for the same year. The fiscal 2025 balance sheet shows $377M in total assets, $185M in cash and $48.3M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $236M | +47.5% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $23.5M | +$74.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$5.3M | +$64.1M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $68.0M | +$109M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $291,000 | +781.8% | FY20252025-12-31 |
| Total assetsAssets | $377M | +70.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $32.6M | +$81.8M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $185M | +256.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $48.3M | +24.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $53.5M | −$9.1M | Open → |
| Q2 20262026-06-30 | $49.1M | −$8.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Akebia Therapeutics, Inc.
- Ticker
- AKBA
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001517022
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Staar SurgicalSTAA | $239M | −$80.4M |
| VaxartVXRT | $237M | $16,327 |
| OrthopediatricsKIDS | $236M | −$39.6M |
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
| AnaptysbioANAB | $235M | −$13.2M |
| CerusCERS | $234M | −$15.6M |
| TalkspaceTALK | $229M | $7.8M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Akebia Therapeutics — Key figures |url=https://companiesranked.com/en/company/akebia-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Akebia Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/akebia-therapeuticsBibTeX
@misc{companiesranked-en-company-akebia-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Akebia Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/akebia-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001517022-26-000020 · February 26, 2026
{{cite web |title=Akebia Therapeutics — Key figures — 10-K (0001517022-26-000020) |url=https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.